guselkumab,ixekizumab,dupilumab,bimekizumab,apremilast,secukinumab,upadacitinib,deucravacitinib,risankizumab
boehringer ingelheim,amgen,regeneron,janssen,bms,novartis,ucb biopharma,eli lilly,sanofi,abbvie
['deucra', 'guselkumab', ' psa', 'bimekizumab', 'risan', 'ixekizumab', 'upadacitinib', 'psoriasis', 'secukinumab', 'apremilast', 'dupilumab', 'derm']
congress #aad2023 | presented cases to highlight management approaches for challenging clinical situations, with some tips on combination therapy and switching. #psoriasis #psoriaticarthritis #dermtwitter 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource that provides balanced and up-to-date medical education. #Psoriasis #RheumTwitter